Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis
| Autor: | Hao Qin, Yuan-Ping Zhu, Jie Luo, Weiqiang Yang, Hai-li Xie, Wen-Bin Lei |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Epidemiology medicine.medical_treatment Cancer Treatment lcsh:Medicine Antineoplastic Combined Chemotherapy Protocols Odds Ratio Clinical Epidemiology lcsh:Science Multidisciplinary Statistics Induction Chemotherapy Head and Neck Tumors Survival Rate Fluorouracil Head and Neck Neoplasms Medicine Taxoids PF Regimen Cancer Epidemiology medicine.drug Research Article medicine.medical_specialty Drugs and Devices Clinical Research Design Biostatistics Internal medicine medicine Humans Survival rate Biology Chemotherapy Models Statistical Population Biology business.industry Pharmacoepidemiology Head and neck cancer lcsh:R Induction chemotherapy Cancers and Neoplasms Chemotherapy and Drug Treatment medicine.disease Regimen Otorhinolaryngology Head and Neck Cancers lcsh:Q Cisplatin Meta-Analyses business Febrile neutropenia Mathematics |
| Zdroj: | PLoS ONE, Vol 7, Iss 12, p e51526 (2012) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | BACKGROUND: Some investigations have suggested that induction chemotherapy with a combination of taxanes, cisplatin and fluorouracil (TPF) is effective in locally advanced head and neck cancer. However, other trials have indicated that TPF does not improve outcomes. The objective of this study was to compare the efficacy and safety of TPF with a cisplatin and fluorouracil (PF) regimen through a meta-analysis. METHODS: Four randomized clinical trials were identified, which included 1,552 patients with locally advanced head and neck cancer who underwent induction chemotherapy with either a TPF or PF protocol. The outcomes included the 3-year survival rate, overall response rate and different types of adverse events. Risk ratios (RRs) and their 95% confidence intervals (CIs) were pooled using RevMan 5.1 software. RESULTS: The 3-year survival rate (51.0% vs. 42.4%; p = 0.002), 3-year progression-free survival rate (35.9% vs. 27.2%; p = 0.007) and overall response to chemotherapy (72.9% vs. 62.1%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|